Another CAR T-Cell Clinical Trial Open to Neuroendocrine Cancer Patients
A phase I CAR T-cell clinical trial targeting the molecule IL13Rα2 found on the surface of some tumors is being conducted at the University of
The Neuroendocrine Tumor Research Foundation directs your individual donations to breakthrough scientific research. Since 2005, we have funded $37.6 million in research projects. The Neuroendocrine Research Foundation is a 501(c)(3) organization, so all donations are fully tax-deductible to the extent allowed by law. We are grateful to you for your generosity.
The Neuroendocrine Tumor Research Foundation directs your individual donations to breakthrough scientific research. Since 2005, we have funded $37.6 million in research projects. The Neuroendocrine Research Foundation is a 501(c)(3) organization, so all donations are fully tax-deductible to the extent allowed by law. We are grateful to you for your generosity.
A phase I CAR T-cell clinical trial targeting the molecule IL13Rα2 found on the surface of some tumors is being conducted at the University of
The Neuroendocrine Tumor Research Foundation is excited to share an important update in the field of neuroendocrine tumor (NET) treatment. On August 6, 2024, Exelixis
A new first-in-human clinical trial at the National Institutes of Health in Bethesda, Maryland, is exploring the use of an antibody-drug conjugate (ADC), ADCT-701, in
The U.S. Food and Drug Administration approved Lutathera® as the first therapy specifically for patients 12 to 17 years of age who have somatostatin receptor-positive
The U.S. Food and Drug Administration recently authorized a new technology called histotripsy to treat tumors in the liver, including neuroendocrine tumors. The noninvasive Edison®
A key tenet of NETRF’s mission is to help NET patients navigate the challenges of living with NET cancer. Participating in a clinical trial can
BE HEARD: Share your story with staff of the FDA about your experience or your loved one’s living with #CarcinoidSyndrome (CS). #FDA’s Patient Affairs and NORD are hosting
Additional US study sites are now participating in an ongoing clinical trial of peptide receptor radionuclide therapy (PRRT) with 177Lu-edotreotide as a first or second
Brittany Holzhauer had her whole future planned. A self-professed “dreamer” with incredible determination, she started her career as pharmacist in 2018 and with her husband Luke, welcomed her first child, Lorelei, in June of 2019.
“In 2012, my husband was diagnosed with a neuroendocrine tumor (NET) cancer. At that time, there was little information and few treatment options,” said Suzanne Ludlow, NETRF Board Member and generous benefactor of NETRF’s second edition of “Neuroendocrine Cancer: A Guide for Patients and Families.” Suzanne lost her beloved husband Vincent in 2017, but she’s honoring his life while supporting other patients and families navigating NETs as a new member of the NETRF Board of Trustees. Read more about Suzanne and Vincent’s story here.